Terms of Reference
Hepatitis C: Collaboration Task & Finish group
Hepatitis C Treatment CollaborativeTask & Finish group: Forming a Commissioning Strategy for treatment for patients with Hepatitis C in England
Purpose
Hepatitis C: Collaboration Task & Finish group is established to advise NHS England on the commissioning of treatment for hepatitis C and provide context across all the issues related to hepatitis C. It will produce an “Examination of Issues”report relating to the treatment strategies of hepatitis C. For each issue identified it will define the strategy and mitigation and identify the body who will take lead on delivery. It will consider and make recommendations to support commissioning of treatment for chronic hepatitis C infection to maximize reduction in harm for patients within the available resource.
Role
- To define the issues relating to hepatitis C identification, management and treatment and the differing patient populations affected;
- To determine the strategic actions for each issue and define the responsible body to deliver; and
- To consider the commissioning responsibility of NHS England, CCGs and Local authorities.
Context
- To understand the drug pipeline and range of new treatment regimens;
- To outline patient pathways leading into treatment and where these are sited; and
- To outline the commissioning pathways involved in commissioning services for patients with hepatitis C
Demand
- To understand the drivers for demand for treatment of hepatitis C
- To understand the patient populations requiring treatment
Timing of Treatment
- To understand the impact of timing oftreatment for the patient
- To understand the impact of timing of treatment on the residual infection in the population
Patient Pathway
- To understand the role of hepatitis networks
- To understand the impact of new treatments on the current patient pathway
- To understand the cost impact of new treatments on the cost of the current pathway
Other
- As determined by the group
Analysis
- To provide a summary of the sources and volume of demand
- To model the impact on volume of different commissioning approaches to treatment and the timing of treatment
- To model the impact on outcomes
- To model the impact on reduction of harm/disease
- To model the cost of different approaches and cost impact on the current pathway
Outputs
- To have a shared understanding of the issues
- To commission further analysis to support commissioning decisions
- To develop a unified policy direction for the treatment of Hepatitis C that can be used across commissioning bodies and shared with key stakeholders
Membership:
Chair: Celia Ingham Clark, Director for Reducing Premature Mortality
NHS England, Specialised Services
Ursula Peaple, Programme Director, Internal Medicine(Interim)
Malcolm Qualie,Pharmacy Advisor
Michael Glynn, NCD Liver
Rosemarie Lindo,Internal Medicine Project Support Officer
Public Health Specialized,Jose Figueroa,
London Region Commissioning Team
Simon Williams
NHS England Health & Justice:
Kate Davies Commissioner
George Leahy Public Health Consultant
NHS England,Specialised Commissioning Clinical Reference Groups
Dr Peter Moss,Chair, Infectious Diseases
Dr Graham Foster,Deputy Chair, Hepatobiliary
Patient Representative
Charles Gore, Chief Executive of the Hepatitis C Trust
NHS England Specialised Commissioning Operations
Finance Peter Heywood, Commercial & Technical Delivery
Ethicist: requested
Provider representative from
Public Health England
Eamonn O’Moore, Director for Health & Justice
Dr Sema Mandal, Consultant Epidemiologist, Viral Hepatitis Lead
Dr Helen Harris, Clinical Scientist (Epidemiology) Research Associate
NICE Appraisals
Meindert Boysen, Associate Director
Elizabeth George)
Helen Knight ) Programme Team
)
Department of Health
Rowena Jecock, DH Blood Policy
Ben Cole, DH Policy
Office of CCGs
Peter Kohn, Director
Analytics Support
Loraine Hawkins/John Brittain, Information Health Economist
Local Government Association – requested but no response
Governance
The Hep C treatment T&F Group will report to NHS England Specialised Commissioning Taskforce
Meeting Arrangements
The Group will meet as required. Given the geographical distribution of members, meetings will be 2x face to face and 2 x webinar conference
25 November 2014